Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (1-10 of 433) with videos related to

Pageof 44
Sort By:
Diabetes|May 29, 2010
Comment on: Villareal et al. (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes;59:479-485Filip K Knop
Diabetes Care|March 31, 2011
Comment on: Chen et al. utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 2010;33:2552–2554Filip K Knop
European Journal of Endocrinology|April 22, 2018
EJE PRIZE 2018: A gut feeling about glucagonFilip K Knop
American Journal of Physiology. Endocrinology and Metabolism|April 29, 2010
Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?Filip K Knop
The Journal of Clinical Endocrinology and Metabolism|October 21, 2019
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid PhysiologyAndreas Brønden, Filip K Knop
Nature Reviews. Endocrinology|August 29, 2012
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?Mikkel Christensen, Filip K Knop
Diabetes Care|July 25, 2013
Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restrictionFilip K Knop, Roy Taylor
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Current Diabetes Reports|April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?Mikkel Christensen, Filip K Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Pageof 44

Showing results (1-10 of 433) with videos related to

Sort By:
Pageof 44
Diabetes|May 29, 2010
Comment on: Villareal et al. (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes;59:479-485Filip K Knop
Diabetes Care|March 31, 2011
Comment on: Chen et al. utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 2010;33:2552–2554Filip K Knop
European Journal of Endocrinology|April 22, 2018
EJE PRIZE 2018: A gut feeling about glucagonFilip K Knop
American Journal of Physiology. Endocrinology and Metabolism|April 29, 2010
Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?Filip K Knop
The Journal of Clinical Endocrinology and Metabolism|October 21, 2019
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid PhysiologyAndreas Brønden, Filip K Knop
Nature Reviews. Endocrinology|August 29, 2012
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?Mikkel Christensen, Filip K Knop
Diabetes Care|July 25, 2013
Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restrictionFilip K Knop, Roy Taylor
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Current Diabetes Reports|April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?Mikkel Christensen, Filip K Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Pageof 44